Core Viewpoint - The agreement between Pulsenmore and Clalit aims to revolutionize fertility care by allowing patients to perform follicular monitoring scans from home, enhancing convenience and maintaining clinical oversight [1][4]. Group 1: Agreement Details - Pulsenmore and Clalit will establish an end-to-end clinical service through Beilinson NEXT, enabling eligible patients to conduct follicular monitoring scans at home with real-time guidance [1]. - The agreement allows both companies to market Pulsenmore FC directly to patients, facilitating access to at-home fertility monitoring [1]. Group 2: Product Overview - Pulsenmore FC is a patient-operated ultrasound device designed for at-home follicular monitoring, transmitting scan data securely to the Beilinson NEXT care team for remote interpretation [3]. - The device aims to reduce the need for frequent in-clinic visits during IVF and fertility preservation cycles, thus minimizing disruption to patients' daily lives [3]. Group 3: Clinical Study Results - A controlled clinical study at Beilinson Medical Center reported a strong safety profile for Pulsenmore FC, showing high concordance between at-home measurements and in-clinic assessments [2]. Group 4: Strategic Vision - Clalit’s CEO emphasized that the new service aligns with their strategic vision of providing medical services from home, ensuring quality comparable to hospital settings [5]. - The service is expected to enhance the experience for women and couples undergoing fertility treatments, addressing the emotional and physical complexities involved [5]. Group 5: Future Developments - Pulsenmore has also supplied Clalit with its physician-supervised home prenatal ultrasound solution, Pulsenmore ES, which has received FDA De Novo authorization [5]. - A binding agreement for an additional 25,000 Pulsenmore ES units over five years has been signed, indicating a commitment to expanding their service offerings [5].